Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.

IF 3.7 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal Pub Date : 2024-12-21 DOI:10.1016/j.ahj.2024.12.006

Adam J Nelson, Lisa A Kaltenbach, Darren K McGuire, Monica Levya, Hussein R Al-Khalidi, Laura Webb, Renato D Lopes, Rodica Pop-Busui, Matthew A Cavender, Vanita R Aroda, Melissa L Magwire, Caroline R Richardson, Ildiko Lingvay, Julienne K Kirk, Ambarish Pandey, Tanya Gaynor, Jonathan Pak, Alana Washington, Cagri Senyucel, Jennifer B Green, Christopher B Granger, Neha J Pagidipati

引用次数: 0

Abstract

SGLT-2i and GLP-1RA are recommended for persons with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) but are underused in clinical practice. The COORDINATE-Diabetes randomized clincal trial evaluated a multi-faceted intervention to increase the use of evidence-based therapies for reducing cardiovascular risk among participants with diabetes and atherosclerotic cardiovascular disease. This analysis reports the discontinuation rate of SGLT-2i and GLP-1RA in follow up and summarises the clinician-reported reasons underlying these decisions.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

American heart journal 医学-心血管系统

CiteScore

8.20

自引率

2.10%

发文量

214

审稿时长

38 days

期刊介绍： The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.